Oncotype DX in BRCA-mutated Breast Cancer Patients: Our Experience. A Retrospective Observational Monocentric Study

Plain-language summary

This study retrospectively evaluates the use of the Oncotype DX test in breast cancer patients carrying a BRCA mutation. It included women aged 18 and older who had surgery for ER-positive, HER2-negative early-stage breast cancer. It was an observational study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

IRCCS San Raffaele

Intervention

Oncotype DX assay

Start date

1/1/2012

Estimated completion

6/30/2022

Countries

Italy

Related genes

Locations

• Milan, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age at diagnosis at least 18 years
* Women who underwent breast surgery in OSR
* Patients with ER-positive, HER2-unamplified early-stage BC who underwent the Oncotype DX assay, according to the standard of care.

Exclusion Criteria:

* Male
* ER negative or HER2 amplified disease
* Patient s who did not undergo breast surgery in OSR
* Patient s who did not undergo the Oncotype Dx assay